Founded in 2020 as a spin-off of Hospital Clínic Barcelona and IDIBAPS, Gyala Therapeutics is advancing novel cell therapies that address unmet needs in blood cancers. Its lead candidate, GYA01, is a first-in-class CAR-T targeting the CD84 protein, which is highly over-expressed in acute myeloid leukemia, T-cell acute lymphoblastic leukemia, and other hematologic malignancies. The company has received authorization from the Spanish Agency of Medicines and Medical Devices to begin a Phase I/IIa clinical trial of GYA01 at Hospital La Fe in Valencia and Hospital Clínic Barcelona. Gyala plans to use its newest capital to accelerate this trial, with Dr. Pau Montesinos and Dr. Jordi Esteve serving as principal investigators. To date, the biotech has secured €11 million in equity financing from Invivo Partners, Nara Capital, and CDTI Innvierte, supplemented by several Spanish innovation grants such as NEOTEC and Public-Private Collaboration Projects. The latest non-dilutive award brings total capital raised to roughly €14.7 million.

Total raised

$8M

Funding rounds

2

Latest round

Grant

Latest activity

Feb 2026